Payment overview · 2025
General Payments
$620.62
27 reported records · 17 companies
Healthcare provider profile · identity verified
Volkan Sumer, DO
Allopathic & Osteopathic Physicians|Family Medicine · PEKIN, IL · NPI 1730185125
Verified facts
What the public records show
CMS Open Payments records show Volkan Sumer, DO received $620.62 in general payments during 2025 across 27 reported records.
Novo Nordisk Inc accounted for 17.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Linzess, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 206 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $110.00 | 17.7% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $87.36 | 14.1% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $74.98 | 12.1% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $58.26 | 9.4% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $37.51 | 6.0% | 2 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $30.83 | 5.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.39 | 4.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $25.33 | 4.1% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $22.97 | 3.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.80 | 3.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $20.69 | 3.3% | 1 | 2025 |
| Avanos Medical | Unresolved — no canonical attribution shown | $20.40 | 3.3% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.38 | 3.1% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.40 | 2.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.21 | 2.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.48 | 2.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.63 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $620.62 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $74.98 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $71.75 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $40.05 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $37.72 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $37.51 | 2 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $32.37 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $30.83 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $28.94 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $26.39 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $25.33 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $22.97 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.80 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $20.69 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.54 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.54 | 1 | 2025 |
Source payment records
|
|||||
| GENVISC 850 SODIUM HYALURONATE Normalized: genvisc 850 sodium hyaluronate |
Device | Avanos Medical | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $19.38 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $19.38 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $18.37 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $18.37 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $17.40 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.21 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $16.48 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 48 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 53 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
68 | 14 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 13 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
206 | 37 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
53 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 656 | 153 |
| Atorvastatin Calcium | Atorvastatin Calcium | 535 | 134 |
| Tramadol Hcl | Tramadol Hcl | 496 | 105 |
| Omeprazole | Omeprazole | 457 | 113 |
| Alprazolam | Alprazolam | 427 | 84 |
| Lorazepam | Lorazepam | 419 | 85 |
| Lisinopril | Lisinopril | 416 | 104 |
| Amlodipine Besylate | Amlodipine Besylate | 409 | 99 |
| Simvastatin | Simvastatin | 358 | 94 |
| Metformin Hcl | Metformin Hcl | 330 | 85 |
| Hydrochlorothiazide | Hydrochlorothiazide | 299 | 78 |
| Metoprolol Tartrate | Metoprolol Tartrate | 266 | 56 |
| Gabapentin | Gabapentin | 257 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 252 | 66 |
| Montelukast Sodium | Montelukast Sodium | 246 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 231 | 64 |
| Zolpidem Tartrate | Zolpidem Tartrate | 229 | 43 |
| Furosemide | Furosemide | 228 | 59 |
| Losartan Potassium | Losartan Potassium | 218 | 60 |
| Eliquis | Apixaban | 206 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 173 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 171 | 43 |
| Meloxicam | Meloxicam | 163 | 52 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 161 | 61 |
| Sertraline Hcl | Sertraline Hcl | 156 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 154 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 145 | 34 |
| Donepezil Hcl | Donepezil Hcl | 131 | 28 |
| Fenofibrate | Fenofibrate | 131 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 127 | 37 |
| Warfarin Sodium | Warfarin Sodium | 123 | 21 |
| Alendronate Sodium | Alendronate Sodium | 122 | 24 |
| Potassium Chloride | Potassium Chloride | 115 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 112 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 109 | 30 |
| Pregabalin | Pregabalin | 104 | 19 |
| Glipizide | Glipizide | 101 | 28 |
| Allopurinol | Allopurinol | 98 | 25 |
| Carvedilol | Carvedilol | 96 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 92 | 22 |
| Clonazepam | Clonazepam | 89 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 26 |
| Celecoxib | Celecoxib | 74 | 16 |
| Glipizide Er | Glipizide | 69 | 14 |
| Synthroid | Levothyroxine Sodium | 68 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 64 | 24 |
| Atenolol | Atenolol | 55 | 15 |
| Finasteride | Finasteride | 55 | 14 |
| Trazodone Hcl | Trazodone Hcl | 53 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 51 | 12 |
| Ezetimibe | Ezetimibe | 50 | 12 |
| Lovastatin | Lovastatin | 50 | 12 |
| Irbesartan | Irbesartan | 49 | 13 |
| Azithromycin | Azithromycin | 48 | 38 |
| Famotidine | Famotidine | 48 | suppressed |
| Jardiance | Empagliflozin | 48 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 47 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 47 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 47 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 46 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | suppressed |
| Xarelto | Rivaroxaban | 45 | suppressed |
| Diazepam | Diazepam | 44 | suppressed |
| Glimepiride | Glimepiride | 44 | 12 |
| Januvia | Sitagliptin Phosphate | 44 | suppressed |
| Methylprednisolone | Methylprednisolone | 44 | 39 |
| Mirtazapine | Mirtazapine | 44 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 43 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 40 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 24 |
| Nabumetone | Nabumetone | 38 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 34 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 33 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 33 | suppressed |
| Cefdinir | Cefdinir | 33 | 32 |
| Testosterone | Testosterone | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Lamotrigine | Lamotrigine | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Primidone | Primidone | 28 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 21 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Prednisone | Prednisone | 23 | 19 |
| Amoxicillin | Amoxicillin | 22 | 11 |
| Eszopiclone | Eszopiclone | 22 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Calcitriol | Calcitriol | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 13 |
| Estradiol | Estradiol | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Indapamide | Indapamide | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Trimethoprim | Trimethoprim | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Mesalamine Dr | Mesalamine | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 12 |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Dextroamphetamine Sulfate Er | Dextroamphetamine Sulfate | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $620.62 · 27 records | Novo Nordisk Inc | BREZTRI, CAMZYOS, CREON, Cologuard Collection Kit, ENTRESTO, EVENITY, FUROSCIX, GEMTESA, GENVISC 850 SODIUM HYALURONATE, JARDIANCE, KISUNLA, LEQVIO, LINZESS, NUZYRA, OTEZLA, Ozempic, PROLIA, QULIPTA, REPATHA, REXULTI, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, Veozah, Wegovy, XHANCE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error